Replimune

$22.0M revenue • 120 employees • 500 Unicorn Park Dr, 3rd Floor, Woburn, MA, 01801, United States

Last Updated May 8, 2025

Company Overview

Company Name

Replimune

Address

500 Unicorn Park Dr, 3rd Floor, Woburn, MA, 01801, United States

Approx. Annual Revenue

$22.0M

Employees

120

Established

2015

Locations

2

About Replimune

Replimune is a biotechnology company based in Woburn, Massachusetts that is pioneering the development of novel tumor-directed oncolytic immunotherapies. Their mission is to revolutionize cancer treatment by activating a powerful and durable full-body anti-tumor immune response. Replimune has multiple ongoing clinical trials evaluating the safety and effectiveness of their investigational therapies in a range of solid tumor cancers.

Business Profile

Read from the Replimune website on Oct 14, 2026. Hover an item to see the exact wording it came from.

About the website

Website quality (AI-assessed)
8/10 · Current copyright 2026; Complete company and careers pages
Footer copyright year
2026

Recent changes

What changed on the Replimune website and Google listing, as detected by Coldlytics on each visit.

  1. Estimated revenue band moved from $1M-2.5M to $10M-25M

  2. Estimated headcount moved from 6-10 to 101-250 employees

Coldlytics tracks changes like these across millions of businesses, so you can reach companies the moment they add a pixel, start hiring, or switch software.

Find companies by what just changed →

Replimune locations

2 Google Business Profile listings.

LocationGoogle categoryReviewsStatus
500 Unicorn Park Dr, 3rd Floor, Woburn, MAprimary———
69-70 Innovation Dr, Milton, Abingdon— 4.0 (1)Claimed

Biotech & Life Sciences Companies near Woburn, MA

Browse all Biotech & Life Sciences companies in Massachusetts →

Frequently Asked Questions about Replimune

Categories

Technologies Used

Social Profiles

Key Decision Makers

Sushil Patel Chief Executive Officer
LinkedIn
Susan Navia Senior Clinical Trial Manager
LinkedIn
Roberto Cabrera Manager, Clinical Trial Agreements
LinkedIn